EA025148B1 - БИСПЕЦИФИЧЕСКИЕ СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С VEGF И Ang2 - Google Patents

БИСПЕЦИФИЧЕСКИЕ СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С VEGF И Ang2 Download PDF

Info

Publication number
EA025148B1
EA025148B1 EA201301108A EA201301108A EA025148B1 EA 025148 B1 EA025148 B1 EA 025148B1 EA 201301108 A EA201301108 A EA 201301108A EA 201301108 A EA201301108 A EA 201301108A EA 025148 B1 EA025148 B1 EA 025148B1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding
ueor
unn
single variable
domain
Prior art date
Application number
EA201301108A
Other languages
English (en)
Russian (ru)
Other versions
EA201301108A1 (ru
Inventor
Андреас Гшвинд
Рене Георг Отт
Жоашен Букно
Мари-Анж Бюйз
Эрик Депла
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45895502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA025148(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201301108A1 publication Critical patent/EA201301108A1/ru
Publication of EA025148B1 publication Critical patent/EA025148B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201301108A 2011-04-01 2012-03-30 БИСПЕЦИФИЧЕСКИЕ СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С VEGF И Ang2 EA025148B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11160921 2011-04-01
PCT/EP2012/055901 WO2012131078A1 (en) 2011-04-01 2012-03-30 Bispecific binding molecules binding to vegf and ang2

Publications (2)

Publication Number Publication Date
EA201301108A1 EA201301108A1 (ru) 2014-03-31
EA025148B1 true EA025148B1 (ru) 2016-11-30

Family

ID=45895502

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201301108A EA025148B1 (ru) 2011-04-01 2012-03-30 БИСПЕЦИФИЧЕСКИЕ СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С VEGF И Ang2
EA201600338A EA036746B1 (ru) 2011-04-01 2012-03-30 Биспецифическая связывающая молекула, связывающаяся с vegf и ang2

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201600338A EA036746B1 (ru) 2011-04-01 2012-03-30 Биспецифическая связывающая молекула, связывающаяся с vegf и ang2

Country Status (36)

Country Link
US (4) US9527925B2 (enExample)
EP (2) EP3144322A3 (enExample)
JP (2) JP6023786B2 (enExample)
KR (1) KR101907572B1 (enExample)
CN (2) CN105820243A (enExample)
AP (1) AP2013007085A0 (enExample)
AR (1) AR085984A1 (enExample)
AU (2) AU2012237234B2 (enExample)
BR (1) BR112013025304B1 (enExample)
CA (1) CA2827817C (enExample)
CL (1) CL2013002623A1 (enExample)
CO (1) CO6801639A2 (enExample)
CY (1) CY1118339T1 (enExample)
DK (1) DK2694546T3 (enExample)
EA (2) EA025148B1 (enExample)
EC (1) ECSP13013001A (enExample)
ES (1) ES2606302T3 (enExample)
HK (1) HK1225400A1 (enExample)
HR (1) HRP20161689T1 (enExample)
HU (1) HUE030148T2 (enExample)
IL (1) IL227936B (enExample)
LT (1) LT2694546T (enExample)
MA (1) MA34979B1 (enExample)
MX (2) MX343440B (enExample)
MY (1) MY171007A (enExample)
PE (1) PE20140448A1 (enExample)
PH (1) PH12013502044A1 (enExample)
PL (1) PL2694546T3 (enExample)
PT (1) PT2694546T (enExample)
RS (1) RS55361B1 (enExample)
SG (2) SG10201602373TA (enExample)
SI (1) SI2694546T1 (enExample)
TN (1) TN2013000390A1 (enExample)
UA (1) UA114707C2 (enExample)
UY (1) UY33998A (enExample)
WO (1) WO2012131078A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2648164C1 (ru) * 2016-12-19 2018-03-22 Федеральное государственное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Селективный бифункциональный препарат на основе фрагментов одноцепочечных антител верблюжьих, нацеленный на опухолевые рецепторы cd47/erbb2, предназначенный для терапии злокачественных новообразований

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
HUE044263T2 (hu) * 2012-03-30 2019-10-28 Boehringer Ingelheim Int ANG2-kötõ molekulák
EP2872534B1 (en) 2012-07-13 2018-08-08 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
JP2015532272A (ja) * 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
WO2014049100A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
JP6313530B1 (ja) * 2015-01-16 2018-04-18 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 標的化成分及びエフェクター成分を有する分子構築物
AR103477A1 (es) 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
CN107454905B (zh) 2015-03-31 2023-04-28 索里索制药公司 多肽
CN107427577A (zh) 2015-03-31 2017-12-01 韦斯夸尔德有限公司 具有蛋白酶可切割接头的肽构建体
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
RU2749674C2 (ru) * 2015-07-29 2021-06-16 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь
WO2017030909A1 (en) * 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
CN108137681B (zh) * 2015-09-23 2024-06-18 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
LT3374392T (lt) * 2015-11-13 2022-01-25 Ablynx Nv Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
LT3383425T (lt) 2015-12-04 2020-10-12 Boehringer Ingelheim International Gmbh Biparatopiniai polipeptidai, veikiantys antagonistiškai wnt signaliniam keliui vėžinėse ląstelėse
KR102543878B1 (ko) * 2016-08-23 2023-06-14 메디뮨 리미티드 항-ｖｅｇｆ-ａ 및 항-ａｎｇ2 항체 및 이의 용도
EP3504236B1 (en) * 2016-08-23 2020-09-23 Medimmune Limited Anti-vegf-a antibodies and uses thereof
AU2017378398B2 (en) * 2016-12-14 2023-02-02 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
EP3630816B1 (en) 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonizing wnt signaling in tumor cells
CA3061053A1 (en) * 2017-06-02 2018-12-06 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy
CN119770646A (zh) 2018-02-06 2025-04-08 豪夫迈·罗氏有限公司 眼科疾病的治疗
WO2019246273A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
EP3813864A4 (en) 2018-06-29 2022-07-20 Gensun Biopharma Inc. Antitumor antagonists
KR102467349B1 (ko) 2018-10-29 2022-11-16 에프. 호프만-라 로슈 아게 항체 제형
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법
MX2021015761A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
MX2021015762A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Composiciones.
WO2020263312A1 (en) 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
WO2021119551A1 (en) 2019-12-11 2021-06-17 Cullinan Oncology, Inc. Anti-cd19 antibodies and multi-specific binding proteins
JP7734132B2 (ja) * 2019-12-11 2025-09-04 カリナン セラピューティクス インコーポレイテッド 抗血清アルブミン抗体
WO2021155151A1 (en) * 2020-01-29 2021-08-05 The Methodist Hospital System Multivalent ligands targeting cell surface receptors and force measurement platform for making the same
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
KR20220006010A (ko) 2020-07-07 2022-01-14 주식회사 카나프테라퓨틱스 보체 경로 억제제 및 혈관신생 억제제를 포함하는 융합단백질 및 이의 용도
EP4237423B1 (en) 2020-11-02 2024-12-11 Boehringer Ingelheim International GmbH Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
EP4019548A1 (en) * 2020-12-23 2022-06-29 Vrije Universiteit Brussel Anti lag3 vhhs and their use
CN116897164A (zh) * 2021-02-10 2023-10-17 上海济煜医药科技有限公司 抗vegf抗体及其用途
AR124917A1 (es) * 2021-02-19 2023-05-17 Dotbio Pte Ltd Moléculas de unión a vegfa
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
MX2023014407A (es) * 2021-06-04 2024-04-23 Innovent Biologics Suzhou Co Ltd Molécula de unión biespecífica que se une a vegf y ang2 y uso de la misma.
AU2022327397A1 (en) * 2021-08-13 2024-03-14 Innovent Biologics (Suzhou) Co., Ltd. Anti-vegf a and -vegf c bispecific antibody and use thereof
JP2024534964A (ja) * 2021-09-10 2024-09-26 ソーター・バイオファーマ・プライベイト・リミテッド 抗ａｎｇ２抗体、その調製方法及び使用
CU24770B1 (es) * 2021-12-15 2025-09-01 Ct Ingenieria Genetica Biotecnologia Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos
KR20230105972A (ko) 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
WO2024055995A1 (zh) 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 一种抗vegfa融合蛋白及其制备方法和应用
EP4582447A4 (en) * 2022-09-14 2026-01-21 Quaerite Biopharm Res Beijing Co Ltd ANTI-VEGFA ANTIBODY OR ANTIGEN BINDING FRAGMENT OF THESE AND ITS USE
CN120322464A (zh) * 2022-12-01 2025-07-15 信达生物制药(苏州)有限公司 三特异性融合蛋白及其用途
TW202426052A (zh) * 2022-12-01 2024-07-01 大陸商信達生物製藥（蘇州）有限公司 包含結合ｖｅｇｆ和ａｎｇ２的雙特異性結合分子的製劑以及其用途
WO2024178730A1 (zh) * 2023-03-02 2024-09-06 清华大学 用于抑制脉络膜新生血管的玻璃体内抗vegf可结晶蛋白药物
WO2025111816A1 (en) * 2023-11-28 2025-06-05 Eluminex Biosciences Limited Multispecific fusion proteins targeting angiogenic, inflammatory, and/or fibrotic factors
CN120025456B (zh) * 2024-03-13 2025-11-07 寻济生物科技（北京）有限公司 一种抗vegfa融合构建体及其制备方法和应用
WO2025219504A1 (en) 2024-04-19 2025-10-23 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
WO2026037352A1 (zh) * 2024-08-13 2026-02-19 长春金赛药业有限责任公司 同时结合VEGF及Ang-2的Fc融合蛋白及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068895A1 (en) * 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
WO2007089445A2 (en) * 2006-01-27 2007-08-09 Amgen Inc. Ang2 and vegf inhibitor combinations
US20080242587A1 (en) * 2007-02-27 2008-10-02 Hak-Zoo Kim Fusion proteins binding to vegf and angiopoietin
WO2010040508A1 (en) * 2008-10-08 2010-04-15 F. Hoffmann-La Roche Ag Bispecific anti-vegf/anti-ang-2 antibodies

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5408535A (en) 1993-09-07 1995-04-18 Miles Inc. Video test strip reader and method for evaluating test strips
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-ｖｅｇｆ 항체
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
CA2433877C (en) 2001-01-17 2014-11-18 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
JP2005518805A (ja) 2002-03-01 2005-06-30 ボール・ホーティカルチャラル・カンパニー 花組織においてトランスジーンを発現させるためのｌｉｓプロモーター
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
WO2004024764A1 (en) 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
US20050043220A1 (en) 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
WO2004041862A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
BRPI0518105A (pt) 2004-12-17 2008-11-04 Genentech Inc uso de antagonista da angiogênese e uso de anticorpo anti-vegf
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
DK2444424T3 (en) 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
US8377398B2 (en) 2005-05-31 2013-02-19 The Board Of Regents Of The University Of Texas System Methods and compositions related to determination and use of white blood cell counts
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006287228B2 (en) 2005-09-01 2012-12-13 Alora Biopharma, Inc. Methods for using and identifying modulators of Delta-like 4
JPWO2007043109A1 (ja) 2005-09-30 2009-04-16 富士通株式会社 情報記憶装置
JP5489465B2 (ja) 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
JP2009523460A (ja) 2006-01-24 2009-06-25 ドマンティス リミテッド Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
US7570881B2 (en) 2006-02-21 2009-08-04 Nokia Corporation Color balanced camera with a flash light unit
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
KR20090016762A (ko) 2006-06-06 2009-02-17 제넨테크, 인크. 혈관 발달을 조정하기 위한 조성물 및 방법
CA2654000A1 (en) 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
RS52685B (sr) 2006-08-07 2013-08-30 Regeneron Pharmaceuticals, Inc. Korišćenje antagonista dii4 u ishemijskom oštećenju ili vaskularnoj insuficijenciji
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
EP2069402A2 (en) * 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
AU2007306340A1 (en) 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and use thereof
MX2009004027A (es) 2006-10-20 2009-09-28 Schering Corp Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso.
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
EP2139924B1 (en) * 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2008149147A2 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
EA200901494A1 (ru) 2007-06-06 2010-06-30 Домантис Лимитед Способы селекции протеазоустойчивых полипептидов
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
WO2009055343A2 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
CN104151429B (zh) 2007-11-26 2018-07-10 拜耳知识产权有限责任公司 抗-间皮素抗体及其用途
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CN101965362A (zh) 2008-03-05 2011-02-02 埃博灵克斯股份有限公司 新型抗原结合二聚体-复合物及其制备方法和应用
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
WO2009124931A2 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
ES2713864T3 (es) 2008-06-05 2019-05-24 Ablynx Nv Secuencias de aminoácidos dirigidas contra proteínas de la envuelta de un virus y polipéptidos que comprenden las mismas para el tratamiento de enfermedades virales
HUE032894T2 (hu) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
US8193321B2 (en) 2008-09-03 2012-06-05 Genentech, Inc. Multispecific antibodies
EP2344536A1 (en) 2008-09-19 2011-07-20 MedImmune, LLC Antibodies directed to dll4 and uses thereof
WO2010066836A2 (en) 2008-12-10 2010-06-17 Ablynx Nv Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
CN104374932A (zh) 2009-01-13 2015-02-25 Fio公司 与电子设备和快速诊断测试中的测试盒结合使用的手持诊断测试设备
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
TWI510248B (zh) 2009-06-17 2015-12-01 Abbvie Biotherapeutics Inc 抗－ｖｅｇｆ抗體及其用途
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
CN110227154A (zh) 2010-02-23 2019-09-13 霍夫曼-拉罗奇有限公司 用于治疗卵巢癌的抗血管发生疗法
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
WO2012012499A1 (en) 2010-07-20 2012-01-26 Nurx Pharmaceuticals, Inc. Optical reader system
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
EP2635694A4 (en) 2010-11-02 2015-11-11 Abbott Lab VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
TW201249459A (en) 2011-05-27 2012-12-16 Novartis Ag Method of treating vision disorders
JP6170496B2 (ja) 2011-09-23 2017-07-26 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
HUE044263T2 (hu) * 2012-03-30 2019-10-28 Boehringer Ingelheim Int ANG2-kötõ molekulák
US9292583B2 (en) * 2012-11-27 2016-03-22 Google Inc. Method of displaying search results

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068895A1 (en) * 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
WO2007089445A2 (en) * 2006-01-27 2007-08-09 Amgen Inc. Ang2 and vegf inhibitor combinations
US20080242587A1 (en) * 2007-02-27 2008-10-02 Hak-Zoo Kim Fusion proteins binding to vegf and angiopoietin
WO2010040508A1 (en) * 2008-10-08 2010-04-15 F. Hoffmann-La Roche Ag Bispecific anti-vegf/anti-ang-2 antibodies

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
H. HASHIZUME, B. L. FALCON, T. KURODA, P. BALUK, A. COXON, D. YU, J. V. BREADY, J. D. OLINER, D. M. MCDONALD: "Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 70, no. 6, 15 March 2010 (2010-03-15), pages 2213 - 2223, XP055003824, ISSN: 00085472, DOI: 10.1158/0008-5472.CAN-09-1977 *
JEFFREY L. BROWN, Z. ALEXANDER CAO, MARIA PINZON-ORTIZ, JANE KENDREW, CORINNE REIMER, SHENGHUA WEN, JOE Q. ZHOU, MOHAMMAD TABRIZI,: "A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 9, no. 1, 1 January 2010 (2010-01-01), US, pages 145 - 156, XP002639543, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-09-0554 *
M. M. HARMSEN ; H. J. DE HAARD: "Properties, production, and applications of camelid single-domain antibody fragments", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER, BERLIN, DE, vol. 77, no. 1, 18 August 2007 (2007-08-18), Berlin, DE, pages 13 - 22, XP019560673, ISSN: 1432-0614, DOI: 10.1007/s00253-007-1142-2 *
MARVIN J S, ZHU Z: "BISPECIFIC ANTIBODIES FOR DUAL-MODALITY CANCER THERAPY: KILLING TWO SIGNALING CASCADES WITH ONE STONE", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 09, no. 02, 1 March 2006 (2006-03-01), GB, pages 184 - 193, XP009067444, ISSN: 1367-6733 *
RUDIKOFF S, ET AL.: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 79, 1 March 1982 (1982-03-01), US, pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/pnas.79.6.1979 *
SCHEUER, W. ; THOMAS, M. ; BAEHNER, M. ; SEEBER, S. ; KETTENBERGER, H. ; SCHANZER, J. ; BRINKMANN, U. ; WEIDNER, M. ; REGULA, J. ;: "468 Anti-tumoral and anti-metastatic activity of a tetravalent bispecific antibody (TAvi6) targeting VEGF and Angiopoietin-2", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 8, no. 7, 1 November 2010 (2010-11-01), GB, pages 150 - 151, XP027498158, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(10)72175-3 *
V. R. DOPPALAPUDI, J. HUANG, D. LIU, P. JIN, B. LIU, L. LI, J. DESHARNAIS, C. HAGEN, N. J. LEVIN, M. J. SHIELDS, M. PARISH, R. E. : "Chemical generation of bispecific antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 52, 28 December 2010 (2010-12-28), pages 22611 - 22616, XP055003821, ISSN: 00278424, DOI: 10.1073/pnas.1016478108 *
W. SCHAEFER, J. T. REGULA, M. BAHNER, J. SCHANZER, R. CROASDALE, H. DURR, C. GASSNER, G. GEORGES, H. KETTENBERGER, S. IMHOF-JUNG, : "Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 27, 5 July 2011 (2011-07-05), pages 11187 - 11192, XP055003817, ISSN: 00278424, DOI: 10.1073/pnas.1019002108 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2648164C1 (ru) * 2016-12-19 2018-03-22 Федеральное государственное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Селективный бифункциональный препарат на основе фрагментов одноцепочечных антител верблюжьих, нацеленный на опухолевые рецепторы cd47/erbb2, предназначенный для терапии злокачественных новообразований

Also Published As

Publication number Publication date
AP2013007085A0 (en) 2013-08-31
CY1118339T1 (el) 2017-06-28
IL227936B (en) 2018-06-28
PT2694546T (pt) 2016-12-28
US9527925B2 (en) 2016-12-27
CN103562222B (zh) 2016-04-06
MA34979B1 (fr) 2014-03-01
JP2014515602A (ja) 2014-07-03
EP3144322A2 (en) 2017-03-22
CN103562222A (zh) 2014-02-05
EP2694546B1 (en) 2016-09-21
MY171007A (en) 2019-09-23
AU2017200237B2 (en) 2018-05-17
AU2012237234B2 (en) 2016-10-20
AR085984A1 (es) 2013-11-13
JP6023786B2 (ja) 2016-11-09
MX343440B (es) 2016-11-07
MX337543B (es) 2016-03-10
CO6801639A2 (es) 2013-11-29
ES2606302T3 (es) 2017-03-23
TN2013000390A1 (en) 2015-01-20
CN105820243A (zh) 2016-08-03
MX2013010949A (es) 2014-06-06
PL2694546T3 (pl) 2017-03-31
HK1225400A1 (zh) 2017-09-08
HUE030148T2 (en) 2017-04-28
IL227936A0 (en) 2013-09-30
ECSP13013001A (es) 2013-12-31
JP6297657B2 (ja) 2018-03-20
LT2694546T (lt) 2016-11-10
HRP20161689T1 (hr) 2017-02-24
SI2694546T1 (sl) 2017-01-31
EA036746B1 (ru) 2020-12-16
BR112013025304A2 (pt) 2017-06-06
HK1190412A1 (zh) 2014-07-04
CA2827817A1 (en) 2012-10-04
PE20140448A1 (es) 2014-04-13
EA201301108A1 (ru) 2014-03-31
NZ614249A (en) 2015-05-29
UA114707C2 (uk) 2017-07-25
KR101907572B1 (ko) 2018-10-15
SG193561A1 (en) 2013-11-29
CA2827817C (en) 2020-12-15
US20220017642A1 (en) 2022-01-20
US11161916B2 (en) 2021-11-02
AU2017200237A1 (en) 2017-02-02
DK2694546T3 (en) 2016-12-05
BR112013025304B1 (pt) 2022-10-11
JP2017023152A (ja) 2017-02-02
US10414828B2 (en) 2019-09-17
WO2012131078A1 (en) 2012-10-04
EP3144322A3 (en) 2017-05-31
UY33998A (es) 2012-09-28
AU2012237234A1 (en) 2013-09-05
KR20140018317A (ko) 2014-02-12
US20130078248A1 (en) 2013-03-28
US20170247475A1 (en) 2017-08-31
EP2694546A1 (en) 2014-02-12
SG10201602373TA (en) 2016-05-30
RS55361B1 (sr) 2017-03-31
US20200010569A1 (en) 2020-01-09
EA201600338A1 (ru) 2016-09-30
CL2013002623A1 (es) 2014-02-14
PH12013502044A1 (en) 2013-12-16

Similar Documents

Publication Publication Date Title
EA025148B1 (ru) БИСПЕЦИФИЧЕСКИЕ СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С VEGF И Ang2
JP6678627B2 (ja) 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）多価抗体の組成物および使用方法
JP7273110B2 (ja) 高親和性抗ｖｅｇｆ抗体
EA029277B1 (ru) Vegf-связывающая молекула, кодирующая эту молекулу молекула нуклеиновой кислоты (нк), вектор, содержащий молекулу нк, клетка-хозяин, содержащая молекулу нк или вектор, фармацевтическая композиция, содержащая vegf-связывающую молекулу, и способ производства vegf-связывающей молекулы
US10934350B2 (en) Humanized or affinity-matured anti ang-2 antibody and uses thereof
KR102124142B1 (ko) VEGF-Grab 단백질과 약물의 결합체 및 이의 용도
EP4378954A1 (en) Anti-pvrig/anti-tigit bispecific antibody and application
JP7604379B2 (ja) 抗ｐｄ－１抗体、その抗原結合フラグメントおよびそれらの医薬用途
CN107428838B (zh) 结合tfpi的新型抗体以及包含所述抗体的组合物
EA031182B1 (ru) Ang2-связывающие молекулы
EA019595B1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
MX2014009864A (es) Polipeptidos de union a cx3cr1.
JP2017008060A (ja) 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）抗体の組成物および使用方法
CN103596977B (zh) 结合D114和Ang2的双特异性结合分子
US10280218B2 (en) Antibodies binding to BMP4, and uses thereof
CN116940599A (zh) 抗体融合蛋白及其应用
US11186632B2 (en) Methods of treating cancer using bifunctional molecules that target growth factors
EP4269442A1 (en) Mesothelin binding molecule and application thereof
KR102783248B1 (ko) Cd55에 대한 신규 항체 및 이의 용도
WO2023109888A1 (zh) 抗ang2-vegf双特异性抗体及其用途
KR20150097304A (ko) 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
JP6673847B2 (ja) 癌治療に使用するためのアドレノメデュリンバインダー
EP4177275A1 (en) Coagulation factor xi (fxi) binding protein
JP2024502129A (ja) Ｃｄ５５に対する新規抗体及びその用途
CN121100129A (zh) 新型egfr结合蛋白

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM